Alphatec (NASDAQ:ATEC) COO Scott Lish Sells 19,900 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 19,900 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $19.64, for a total transaction of $390,836.00. Following the completion of the sale, the chief operating officer directly owned 641,432 shares in the company, valued at approximately $12,597,724.48. The trade was a 3.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Scott Lish also recently made the following trade(s):

• On Friday, December 5th, Scott Lish sold 10,875 shares of Alphatec stock. The shares were sold at an average price of $21.47, for a total value of $233,486.25.
• On Thursday, November 20th, Scott Lish sold 25,000 shares of Alphatec stock. The stock was sold at an average price of $19.80, for a total value of $495,000.00.

Alphatec Stock Up 1.5%

Alphatec stock opened at $19.87 on Friday. The business’s 50-day moving average price is $18.90 and its 200 day moving average price is $15.29. The company has a quick ratio of 1.24, a current ratio of 1.99 and a debt-to-equity ratio of 43.02. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -19.11 and a beta of 1.08. Alphatec Holdings, Inc. has a 52 week low of $8.70 and a 52 week high of $22.66.

Alphatec (NASDAQ:ATEC) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.09. The company had revenue of $196.50 million during the quarter, compared to analysts’ expectations of $182.78 million. The company’s revenue for the quarter was up 30.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.28) EPS. As a group, sell-side analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on ATEC shares. Stifel Nicolaus started coverage on shares of Alphatec in a report on Tuesday, October 28th. They issued a “buy” rating and a $20.00 price objective for the company. Wall Street Zen cut Alphatec from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th. HC Wainwright upped their price target on Alphatec from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Wells Fargo & Company raised their price objective on Alphatec from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Finally, Lake Street Capital set a $25.00 target price on Alphatec and gave the company a “buy” rating in a research report on Friday, October 31st. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.45.

Hedge Funds Weigh In On Alphatec

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Alphatec by 0.8% during the first quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company’s stock worth $60,990,000 after purchasing an additional 45,792 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Alphatec by 14.6% during the first quarter. Invesco Ltd. now owns 50,845 shares of the medical technology company’s stock worth $516,000 after buying an additional 6,467 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Alphatec by 68.3% in the first quarter. Russell Investments Group Ltd. now owns 336,463 shares of the medical technology company’s stock valued at $3,412,000 after buying an additional 136,577 shares during the last quarter. Aberdeen Group plc lifted its stake in shares of Alphatec by 5.3% in the first quarter. Aberdeen Group plc now owns 1,131,707 shares of the medical technology company’s stock worth $11,476,000 after buying an additional 56,995 shares in the last quarter. Finally, Northern Trust Corp boosted its position in Alphatec by 3.4% during the first quarter. Northern Trust Corp now owns 1,049,469 shares of the medical technology company’s stock worth $10,642,000 after acquiring an additional 34,726 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.